



MEMORANDUM

TO: Valued STAR and CHIP Providers

FROM: El Paso Health

DATE: 3/12/2024

RE: Change in Preferred Drug List Status for Immunosuppressives, Oral Drug Class Eff. Feb.12

The manufacturer of brand name Rapamune products has confirmed these products were discontinued on Dec. 31, 2023, and some supplies of the products will remain available until early 2024.

HHSC will remove the non-preferred status from the generic sirolimus products on the preferred drug list (PDL). The preferred status of brand name Rapamune products will not change. This will allow existing stock of these medications to be used.

HHSC will remove the non-preferred status for the drugs in the attachment, effective Feb. 12, 2024. These changes will allow providers to prescribe the generic sirolimus products without requiring a PDL prior authorization and continue accessing necessary medication for clients.

List of Oral Immunosuppressives NDCs

NDC	Lable Name
16714018701	SIROLIMUS 0.5 MG TABLET
16714018801	SIROLIMUS 1 MG TABLET
16714018901	SIROLIMUS 2 MG TABLET
55111065301	SIROLIMUS 1 MG TABLET
55111065401	SIROLIMUS 2 MG TABLET
59762100101	SIROLIMUS 0.5 MG TABLET
59762100201	SIROLIMUS 1 MG TABLET



MEMORANDUM

59762100301	SIROLIMUS 2 MG TABLET
60505619702	SIROLIMUS 1 MG/ML SOLUTION
66689034702	SIROLIMUS 1 MG/ML SOLUTION
67877074601	SIROLIMUS 0.5 MG TABLET
67877074701	SIROLIMUS 1 MG TABLET
67877074801	SIROLIMUS 2 MG TABLET
68382035101	SIROLIMUS 1 MG TABLET
68382035201	SIROLIMUS 2 MG TABLET
68382052001	SIROLIMUS 0.5 MG TABLET
68462068201	SIROLIMUS 0.5 MG TABLET
68462068301	SIROLIMUS 1 MG TABLET
68462068401	SIROLIMUS 2 MG TABLET
69238159403	SIROLIMUS 1 MG/ML SOLUTION

If you have any questions regarding this communication please contact our Provider Relations team at 915-532-3778 or email us at ProviderRelationsDG@elpasohealth.com